Search results for "actions"

showing 10 items of 2898 documents

Gestación subrogada y dignidad de la mujer

2018

The situation of the surrogate pregnancy in Spain demands action by our legislators and / or our public authorities. The reason is that the current legal system in which there is a ban of the surrogacy contract is not being attended. In this issue an analysis of the situation in Spain and in other countries is made, to conclude from the right to the dignity of women, that possible actions could be taken to adapt the reality to the legal system.

:CIENCIAS JURÍDICAS [UNESCO]the right to the dignity of womenfiliation. 10 44dignidad de la mujerUNESCO::CIENCIAS JURÍDICASthat possible actions could be taken to adapt the reality to the legal system. Gestación por sustituciónSurrogate pregnancyMaría Dolores The situation of the surrogate pregnancy in Spain demands action by our legislators and / or our public authorities. The reason is that the current legal system in which there is a ban of the surrogacy contract is not being attended. In this issue an analysis of the situation in Spain and in other countries is madeto conclude from the right to the dignity of women2386-4567 22661 Actualidad jurídica iberoamericana 502169 2018 9 6653319 Gestación subrogada y dignidad de la mujer Cervilla Garzónfiliación
researchProduct

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

2020

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA an…

:Chemicals and Drugs::Pharmaceutical Preparations::Placebos [Medical Subject Headings]Physiologyα -lipoic acid ; thioctic acid ; dietary supplement ; safety ; meta-analysisClinical BiochemistryDisease030204 cardiovascular system & hematologyBiochemistrymeta-analysi:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings]Dietary supplementchemistry.chemical_compound0302 clinical medicinethioctic aciddietary supplement meta-analysis safety thioctic acid α-lipoic acid:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]α-lipoic acidLipoic acidSafety profile:Publication Type::Study Characteristics::Meta-Analysis [Medical Subject Headings]Suplementos dietéticosMeta-analysis:Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements [Medical Subject Headings]SafetysafetyAlpha-lipoic acidmedicine.medical_specialtyMEDLINEÁcido tióctico030209 endocrinology & metabolismPlacebo:Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiophenes::Thioctic Acid [Medical Subject Headings]Article:Health Care::Environment and Public Health::Public Health::Accidents::Accident Prevention::Safety [Medical Subject Headings]03 medical and health sciencesα‐lipoic acidThioctic acidInternal medicineDiabetes mellitusmedicineMetaanálisisAdverse effectSeguridad:Diseases::Cardiovascular Diseases [Medical Subject Headings]Molecular Biology:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Volatile [Medical Subject Headings]business.industryRevisión sistemáticalcsh:RM1-950Cell Biologymedicine.disease:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Food Habits::Smoking [Medical Subject Headings]meta-analysisMeta-analysislcsh:Therapeutics. Pharmacologychemistry:Diseases::Nervous System Diseases [Medical Subject Headings]dietary supplementMeta‐analysisbusinessAntioxidants
researchProduct

Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations

2007

Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment o…

:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Veterinary medicine:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Streptomycin [Medical Subject Headings]:Phenomena and Processes::Microbiological Phenomena::Drug Resistance Microbial [Medical Subject Headings]DiseaseGlobal Health:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Health Care::Population Characteristics::Health::World Health [Medical Subject Headings]Terminología como AsuntoBrucellosi:Organisms::Eukaryota::Animals [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::International Agencies::United Nations::World Health Organization [Medical Subject Headings]Policy ForumMedicine in Developing CountriesGentamicinasDrug Resistance MicrobialBrucelosisAdhesión a DirectrizGeneral MedicineHumanosDrug CombinationsAntibacterianosDoxycyclineStreptomycinEstreptomicinaMedicine:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds with 4 or More Rings::Rifamycins::Rifampin [Medical Subject Headings]Drug Therapy CombinationGuideline AdherenceRifampinFluoroquinolonesSalud Mundialmedicine.medical_specialtyEfficacyResultado del TratamientoInvestigación BiomédicaRecurrenciaTherapeuticsWorld Health OrganizationMicrobiologyAntibiotic resistanceTerminology as Topic:Disciplines and Occupations::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings]HumansMedical journalIntensive care medicineDeveloping Countries:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Trimethoprim::Trimethoprim-Sulfamethoxazole Combination [Medical Subject Headings]medicine.diseaseCotrimoxazoleAnimalesQuimioterapia:Humanities::Humanities::History::History Modern 1601-::History 21st Century [Medical Subject Headings]GentamicinsBrucel·losiBiomedical ResearchCommunicable diseases:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 2-Ring::Quinolines::Quinolones::Fluoroquinolones [Medical Subject Headings]Human diseaseRecurrence:Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings]:Information Science::Information Science::Communication::Language::Linguistics::Terminology as Topic [Medical Subject Headings]biologyIraqi patientsRMetaanalysis:Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Brucellosis [Medical Subject Headings]Historia del Siglo XXIAnti-Bacterial AgentsCombinación Trimetoprim-SulfametoxazolTreatment OutcomeInfectious Diseases:Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research [Medical Subject Headings]:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Tetracyclines::Doxycycline [Medical Subject Headings]Fluoroquinolonas:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [Medical Subject Headings]:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins [Medical Subject Headings]Países en Desarrollo:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy Combination [Medical Subject Headings]BrucellaHistory 21st CenturyBrucellosisWorld healthTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimals:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]Resistencia a Medicamentosbusiness.industryOrganización Mundial de la SaludBrucellosisMalalties infecciosesTerapèuticabiology.organism_classificationCombinación de MedicamentosDoxiciclinaTherapybusinessBrucella melitensisPLoS Medicine
researchProduct

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

Latvijas Vēstures Institūta Žurnāls. 2015, Nr. 3 (96)

2015

Valsts kultūrkapitāla fonds

:HUMANITIES and RELIGION::History and philosophy subjects::Archaeology subjects [Research Subject Categories]:HUMANITIES and RELIGION::History and philosophy subjects::History subjects [Research Subject Categories]Latviešu un vācbaltieši starpkaru periodāRecenzijasZinātnes dzīveVēstures avotiLatvia in the Plans and Actions of Polish DiplomacySievietes un vara Padomju LatvijāLatvijas mazpilsētasPersonālijas
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Self-reported antibiotic stewardship and infection control measures from 57 intensive care units: An international ID-IRI survey

2022

Infection control; Multidrug resistance; Stewardship Control de infección; Resistencia a múltiples fármacos; Administración Control d'infecció; Resistència a múltiples fàrmacs; Administració We explored the self-reported antibiotic stewardship (AS), and infection prevention and control (IPC) activities in intensive care units (ICUs) of different income settings. A cross-sectional study was conducted using an online questionnaire to collect data about IPC and AS measures in participating ICUs. The study participants were Infectious Diseases–International Research Initiative (IDI-IR) members, committed as per their institutional agreement form. We analyzed responses from 57 ICUs in 24 countri…

:Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]EpidemiologyIntensive Care UnitInfection controlAmerica:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS]Multidrug resistanceCommunicable DiseasesEnquestesPan drug resistanceCommunicable DiseaseAntimicrobial StewardshipSurveys and QuestionnairesAnti-Bacterial AgentHumansMedicaments antibacterians - Ús terapèuticStewardshipSurveys and QuestionnaireSocietyUnitats de cures intensivesCross-Sectional StudieInfection ControlCross InfectionPreventionPublic Health Environmental and Occupational Health:técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]General MedicineMDROAnti-Bacterial AgentsIntensive Care Units:Health Care Facilities Manpower and Services::Health Facilities::Hospital Units::Intensive Care Units [HEALTH CARE]Cross-Sectional StudiesInfectious Diseases:instalaciones servicios y personal de asistencia sanitaria::centros sanitarios::unidades hospitalarias::unidades de cuidados intensivos [ATENCIÓN DE SALUD]:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS]Self ReportMDROsLow- and upper-middle and high incomeHuman
researchProduct

Search for a common baryon source in high-multiplicity pp collisions at the LHC

2020

Physics letters / B B811, 135849 (2020). doi:10.1016/j.physletb.2020.135849

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]HadronHadron - hadron reactionHEAVY-ION COLLISIONSHigh multiplicityhiukkasfysiikkanucl-exdecay [resonance]01 natural sciencesHigh Energy Physics - ExperimentExperimentHigh Energy Physics - Experiment (hep-ex)hadron–hadron interactions LHC ALICEBarions; strong interaction; LHCALICEstrong resonance decayIonic Collisionsscattering [p p][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentBarionsPION INTERFEROMETRYhadron-hadron scatteringPhysicsLarge Hadron ColliderMesonsHadron - hadron reactionsmass: transversestrong interactionPhysicsbaryon correlations ; invariant radius ; strong hadron–hadron interactions ; strong resonance decayVDP::Kjerne- og elementærpartikkelfysikk: 431RadiusAU+AUInvariant (physics)lcsh:QC1-999quark gluon plasmaPRIRODNE ZNANOSTI. Fizika.HEAVY-ION COLLISIONS; PION INTERFEROMETRY; SIGMA(0) PRODUCTION; AU+AU; COLLISIONS; FEMTOSCOPY; SYSTEMS; PB:Nuclear and elementary particle physics: 431 [VDP]CERN LHC CollVDP::Nuclear and elementary particle physics: 431Transverse massLHCPBParticle Physics - Experimentbaryon correlationsCOLLISIONSNuclear and High Energy Physicsp p: scatteringHigh Energy Physics; ExperimentcollectiveFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]530114 Physical sciencesNuclear physicsHadron - hadron reactions; LHCbaryon baryon: correlationSYSTEMSresonance: decay0103 physical sciencesfemtoscopyddc:530Nuclear Physics - ExperimentHigh Energy Physics010306 general physicshadron hadron: interactioninteraction [hadron hadron]010308 nuclear & particles physicshep-exhadron-hadron scattering ALICE experiment femtoscopySIGMA(0) PRODUCTIONHigh Energy Physics::PhenomenologyALICE experimentcorrelation [baryon baryon]Kaonsstrong hadron–hadron interactionsNATURAL SCIENCES. Physics.invariant radiusBaryonKaons; Ionic Collisions; Mesonstransverse [mass]Antiproton13000 GeV-cms/nucleonHigh Energy Physics::Experimentlcsh:Physicsexperimental results
researchProduct

Scattering Studies with Low-Energy Kaon-Proton Femtoscopy in Proton-Proton Collisions at the LHC

2020

The study of the strength and behaviour of the antikaon-nucleon ($\mathrm{\overline{K}N}$) interaction constitutes one of the key focuses of the strangeness sector in low-energy Quantum Chromodynamics (QCD). In this letter a unique high-precision measurement of the strong interaction between kaons and protons, close and above the kinematic threshold, is presented. The femtoscopic measurements of the correlation function at low pair-frame relative momentum of (K$^+$ p $\oplus$ K$^-$ $\overline{\mathrm{p}}$) and (K$^-$ p $\oplus$ K$^+$ $\overline{\mathrm{p}}$) pairs measured in pp collisions at $\sqrt{s}$ = 5, 7 and 13 TeV are reported. A structure observed around a relative momentum of 58 Me…

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]Protonchiral dynamicsGeneral Physics and Astronomyhiukkasfysiikkanucl-ex01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ALICELHC HBTCorrelation functionHBT[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]scattering [p p]correlation functionKaon-ProtonNuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderPhysicsstrong interactionCHIRAL DYNAMICSVDP::Kjerne- og elementærpartikkelfysikk: 431SIGMA-HYPERON PRODUCTIONddc:3. Good healthPRIRODNE ZNANOSTI. Fizika.p interactions:Nuclear and elementary particle physics: 431 [VDP]CERN LHC CollNUCLEON INTERACTIONSVDP::Nuclear and elementary particle physics: 431P INTERACTIONSIsospinLHC5000 GeV-cms/nucleon 7000 GeV-cms/nucleon 13000 GeV-cms/nucleonpp collisionsParticle Physics - Experimentp p: scatteringStrong interactionLAMBDA(1405)Kaon-Proton Femtoscopy pp collisions LHCFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]Physics and Astronomy(all)Strangenesslambda(1405)114 Physical sciencesALICE; femtoscopyp-pNuclear physicsMomentumALICE LHC High-Energy Physicschiral [model]strangenessnucleon interactionsKaon-Proton ; Femtoscopy ; p-pfemtoscopyquantum chromodynamics0103 physical sciencesNuclear Physics - Experimentddc:530010306 general physicsNuclear Physicsanti-K nucleon: interactionhep-exHigh Energy Physics::PhenomenologySIGMA-HYPERON PRODUCTION; NUCLEON INTERACTIONS; CHIRAL DYNAMICS; P INTERACTIONS; LAMBDA(1405)interaction [anti-K nucleon]mass differenceNATURAL SCIENCES. Physics.Kaon-Proton Femtoscopysigma-hyperon productionHigh Energy Physics::Experimentmodel: chiralexperimental results
researchProduct